Skip to main content

Advertisement

SpringerLink
Log in

Raltegravir resistance in the cerebrospinal fluid

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect. 2012;65:239–45.

    Article  PubMed  Google Scholar 

  2. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. Aids. 2000;14:1949–54.

    Article  PubMed  CAS  Google Scholar 

  3. geno2pheno[resistance]. GENAFOR (Gesellschaft für nachhaltige Forschung). Max Planck Institute. Available at: http://www.geno2pheno.org. Accessed 29 Jan 2013

  4. Watanabe K, Honda M, Watanabe T, et al. Emergence of raltegravir-resistant HIV-1 in the central nervous system. Int J STD AIDS. 2010;21:840–1.

    Article  PubMed  CAS  Google Scholar 

  5. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–65.

    Article  PubMed  CAS  Google Scholar 

  6. Antinori A, Giancola ML, Grisetti S, et al. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. Aids. 2002;16:1867–76.

    Article  PubMed  CAS  Google Scholar 

  7. Christo PP, Greco DB, Aleixo AW, Livramento JA. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era. BMC Infect Dis. 2007;7:147.

    Article  PubMed  Google Scholar 

  8. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819–25.

    Article  PubMed  CAS  Google Scholar 

  9. de Almeida SM, Bhatt A, Riggs PK, et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. J Neurovirol. 2010;16:6–12.

    Article  PubMed  Google Scholar 

  10. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr. 2008;47:544–52.

    Article  PubMed  Google Scholar 

  11. Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. Aids. 2010;24:2412–4.

    PubMed  Google Scholar 

  12. Spudich SS, Huang W, Nilsson AC, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191:890–8.

    Article  PubMed  CAS  Google Scholar 

  13. Yilmaz A, Gisslen M, Spudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE. 2009;4:e6877.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the patient, the nursing and pharmacy staff at the department of HIV and Genitourinary Medicine at St Mary’s Hospital (Imperial College Healthcare NHS Trust, London, UK) and at the Department of HIV, Immunology and Infectious Diseases at St Vincent’s Hospital (Sydney, Australia).

Conflict of interest

AW has received honoraria or research grants, or been a consultant or investigator, in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Roche, Pfizer and ViiV Healthcare. All remaining authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Medicine, Faculty of Medicine, Imperial College London, St Mary’s Hospital Campus, Norfolk Place, London, W2 1PG, UK

    B. Mora-Peris, N. E. Mackie & A. Winston

  2. Department of HIV, Immunology and Infectious Diseases, St Vincent’s Hospital, Sydney, NSW 2010, Australia

    D. Suan, D. A. Cooper & B. J. Brew

  3. Clinical Trials, St Mary’s Hospital, Imperial College London, Praed Street, Winston Churchill Wing, London, W2 1NY, UK

    B. Mora-Peris & A. Winston

Authors
  1. B. Mora-Peris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. E. Mackie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Suan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. A. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. J. Brew
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Winston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to B. Mora-Peris or A. Winston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mora-Peris, B., Mackie, N.E., Suan, D. et al. Raltegravir resistance in the cerebrospinal fluid. Infection 41, 731–734 (2013). https://doi.org/10.1007/s15010-013-0409-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-013-0409-z

Keywords

Search

Navigation